For the quarter ending 2025-12-31.
| Income Statement | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Revenue | - | 100 | 100* | - |
| Research and development | 4,280 | 3,550 | 3,195* | 1,906 |
| General and administrative | 5,165 | 2,501 | 2,029* | 2,973 |
| Total operating expenses | 9,445 | 6,051 | 5,224* | 4,879 |
| Operating loss | -9,445 | -5,951 | -5,124* | -4,879 |
| Interest income | 493 | 267 | 69* | 72 |
| Interest expense | 41 | 36 | 46* | 54 |
| Total other income | 452 | 231 | 23* | 18 |
| Net loss from continuing operations | - | - | -5,102 | -4,861 |
| Loss from discontinued operations | - | - | - | 0 |
| Net loss | -8,993 | -5,720 | -5,102 | -4,861 |
| Other comprehensive gain - unrealized gain on debt securities | 25 | -15 | - | - |
| Comprehensive loss | -8,968 | -5,735 | - | - |
| Basic EPS | -0.09 | -0.11 | -0.392 | -0.49 |
| Diluted EPS | -0.09 | -0.11 | -0.392 | -0.49 |
| Basic Average Shares | 99,133,000 | 52,981,000 | 13,002,000 | 9,862,000 |
| Diluted Average Shares | 99,133,000 | 52,981,000 | 13,002,000 | 9,862,000 |
iBio, Inc. (IBIO)
iBio, Inc. (IBIO)